NCT03197662View on ClinicalTrials.gov

Intranasal Oxytocin vs. Placebo for the Treatment of Hyperphagia in Prader-Willi Syndrome

PHASE2CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

April 11, 2018

Primary Completion Date

August 29, 2022

Study Completion Date

August 29, 2022

Conditions
Prader-Willi SyndromeHyperphagia
Interventions
DRUG

Intranasal Oxytocin (IN-OXT)

Each subject will receive a dose of 16 IU QD, and will be instructed to inhale 2 puffs per nostril every day (4 IU each). If needed, treatment will be titrated due to side effects or non-response.

DRUG

Matched Placebo

Each subject will receive a dose of 16 IU QD, and will be instructed to inhale 2 puffs per nostril every day (4 IU each). If needed, treatment will be titrated due to side effects or non-response.

Trial Locations (1)

10461

Montefiore Medical Center, Albert Einstein College of Medicine, The Bronx

All Listed Sponsors
lead

Eric Hollander

OTHER

NCT03197662 - Intranasal Oxytocin vs. Placebo for the Treatment of Hyperphagia in Prader-Willi Syndrome | Biotech Hunter | Biotech Hunter